Viberzi denied due to quantity / dose limits by Cigna?
Quantity-limit denials usually flip when the appeal documents the clinically appropriate dose for the patient's weight, kidney function, or escalation schedule, citing the FDA label or specialty-society guideline.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for viberzi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on Viberzi
## Why Cigna May Apply Quantity Limits to Viberzi
A quantity-limit denial for Viberzi (eluxadoline) means Cigna's plan will cover the drug but only up to a specified supply within a defined time period — typically a number of tablets per month that reflects the standard dosing schedule in the FDA-approved prescribing label. A denial occurs when a prescription is written for a supply or frequency that exceeds that limit, or when a refill is requested before the allowed refill window.
The most common triggers are: a prescriber writing for a quantity that differs from the labeled dosing schedule, a mail-order vs. retail dispense mismatch, or a plan applying an outdated policy that does not reflect the FDA-approved regimen.
## Why This Denial Is Appealable
If the prescribed quantity directly matches the FDA-approved dosing regimen, the quantity limit may be inconsistent with the approved label and is a strong candidate for appeal. If there is a clinical reason the standard quantity is insufficient — for example, a dosing adjustment documented in the medical record — your prescriber can document that rationale.
## Your Federal Appeal Rights
Under ACA §2719, quantity-limit denials are subject to internal appeal and independent external review. Under ERISA §503, self-funded plans must conduct full-and-fair review. The external-review window is generally approximately four months from the denial notice. Expedited review is available where clinical urgency warrants it.
## The Appeal Process
1. Confirm the exact limit applied. Request in writing the quantity-limit rule Cigna applied and the quantity that was denied. 2. Compare to the FDA-approved label. Obtain the current FDA-approved prescribing label for eluxadoline and confirm what the label states about the approved dosing schedule and quantity. 3. Level 1 internal appeal. Submit a written appeal with the FDA label and a prescriber letter explaining the clinical rationale for the prescribed quantity. 4. External review. Escalate to an IRO if the internal appeal is denied.
## Documentation to Gather
- Prescription details: The exact quantity prescribed, dosing frequency, and day-supply as written by the prescriber.
- FDA prescribing label: The approved dosing section, which defines the medically accepted quantity for the approved indication.
- Prescriber letter: If the prescribed quantity differs from the standard label, a clinical explanation for the variance with chart-based support.
- Pharmacy records: Any prior fills that demonstrate the established regimen.
## Criteria-Mapping Structure
Obtain Cigna's quantity-limit policy for eluxadoline. List the limit that was applied and then directly compare it to the FDA-approved prescribing label's dosing section. If the label supports the prescribed quantity, state that comparison explicitly in the appeal letter. If the prescribed amount is non-standard, provide the specific clinical rationale from the chart. Quantity-limit appeals are often resolved quickly when the FDA label and the prescription are clearly aligned.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →